BCFC/iStock Editorial through Getty Images
- McKesson (NYSE:MCK) stated it would acquire a controlling interest in Core Ventures for $2.49B in money.
- Core Ventures was established by Florida Cancer Specialists & Research Institute (FCS).
- MCK will maintain 70% of the corporate, and after the closing of the deal, Core Ventures will change into a part of the Oncology platform, and monetary outcomes will likely be reported inside McKesson’s U.S. Pharmaceutical phase.
- FCS will retain a minority interest in Core Ventures.
Source: Seekingalpha